Clinical trials: Osimertinib
Non-small Cell Lung Cancer
Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer
Based on the existing research results, Osimertinibi is effective not only for patients with sensitizing EGFR mutations, but also for other less common EGFR mutations.
- Trial name
- NCT03460275
- Testing
- Osimertinib Mesylate Tablets
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer
A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
This trial is a registrational Phase II/III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib in resectable EGFR-mutant non-small cell lung cancer.
- Trial name
- NCT07642024
- Testing
- BL-B01D1, Osimertinib, Carboplatin
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment
Zorifertinib With Osimertinib for NSCLC With Meningeal Progression
This is a clinical trial that aims to test Zorifertinib when used together with a known drug, Osimertinib. The goal is to learn if this combination is safe and works for people with advanced Non-Small Cell Lung Cancer (NSCLC)…
- Trial name
- NCT07361705
- Testing
- Zorifertinib and Osimertinib Combination Therapy
- Where
- 5 sites in China
- Volunteers
- 42 people
- Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
Lung Cancer
A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers
The purpose of this study is to test the safety of combining Osimertinib with either Cisplatin or Carboplatin (at different dose levels) and Etoposide, to find out what effects, if any, this combination of drugs has on people…
- Trial name
- NCT03567642
- Testing
- Osimertinib, Platinum, Etoposide
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
EGFR-TKI Resistant Mutation, Nonsmall Cell Lung Cancer
Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M
The study aims to investigate the efficacy and safety of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI.
- Conditions
- EGFR-TKI Resistant Mutation, Nonsmall Cell Lung Cancer, AZD9291, Brain Metastases
- Trial name
- NCT02972333
- Testing
- AZD9291 80mg oral each day, Radiation therapy
- Volunteers
- 150 people
- Sponsor
- Shandong Cancer Hospital and Institute
Solid Tumor, NSCLC
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.
- Trial name
- NCT04720976
- Testing
- JAB-3312, Binimetinib, Pembrolizumab
- Where
- 15 sites in United States
- Volunteers
- 58 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
This phase II trial tests how well biologically guided radiation therapy (BgRT) and stereotactic body radiation therapy (SBRT) with osimertinib works for the treatment of EGFR positive non-small cell lung carcinoma that has…
- Trial name
- NCT06014827
- Testing
- Biospecimen Collection, Computed Tomography, Osimertinib
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Carcinoma, Non-Small-Cell Lung
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
The objective of this study is to investigate the safety, tolerability, and antitumor activity of novel combination therapies administered in participants with advanced EGFRm NSCLC.
- Trial name
- NCT03381274
- Testing
- Oleclumab, Osimertinib, AZD4635
- Where
- 13 sites in United States, South Korea and 1 more
- Volunteers
- 43 people
- Sponsor
- MedImmune LLC
Metastatic Non-small Cell Lung Cancer
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR.
- Trial name
- NCT04410796
- Testing
- Osimertinib, Carboplatin, Pemetrexed
- Where
- 18 sites in United States
- Volunteers
- 571 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer, Targeted Therapy
AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies
Phase II, single-arm study to assess the safety and efficacy of AZD9291 (80 mg, orally, once daily) in second-line (or later) patients with EGFR mutation-positive, locally advanced or metastatic NSCLC, who have progressed…
- Trial name
- TREM (NCT02504346)
- Testing
- AZD9291
- Where
- 7 sites in Denmark, Finland and 3 more
- Volunteers
- 200 people
- Sponsor
- Oslo University Hospital
Non-Small Cell Lung Cancer
High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
This is a prospective, randomised, uncontrolled phase II clinical trial planned to include 84 subjects with metastatic lung adenocarcinoma that had progressed after first- or second-line treatment with Osmertinib, who were…
- Trial name
- NCT06394674
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Changhai Hospital
Non-small Cell Lung Cancer
Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases
The primary objective is to evaluate the intracranial efficacy of pemetrexed/carboplatin chemotherapy and lazertinib combination therapy after osimertinib failure in EGFR-positive non-small cell lung cancer patients with brain…
- Trial name
- NCT05477615
- Testing
- Lazertinib, Pemetrexed, Carboplatin
- Where
- 6 sites in South Korea
- Volunteers
- 14 people
- Sponsor
- Jin Hyoung Kang
Non-small Cell Lung Cancer
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally…
- Trial name
- TROPION-Lung14 (NCT06350097)
- Testing
- Osimertinib, Datopotamab Deruxtecan
- Where
- 167 sites in United States, Australia and 17 more
- Volunteers
- 582 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLC
This prospective, multicenter patient registry is designed to evaluate the effectiveness and safety of postoperative EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy in patients with completely resected EGFR-mutant high-risk…
- Trial name
- NCT07837739
- Testing
- Adjuvant EGFR-TKI Therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tongji Hospital
EGFR Positive Non-small Cell Lung Cancer
Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC
Tyrosine kinase inhibitors (TKI) have greatly improved prognosis of epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC), with tumor responses in the majority of cases and a median overall survival…
- Trial name
- NCT04105153
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Thoraxklinik-Heidelberg gGmbH
Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis
Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation
Treatment of non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutation is mainly based on tyrosine kinase inhibitors (TKIs) targeting EGFR.
- Conditions
- Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation
- Trial name
- ORBITAL (NCT04233021)
- Testing
- Osimertinib
- Where
- 36 sites in France
- Volunteers
- 57 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Lung Cancer
Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC
This is a prospective, multicenter, randomized, open label study to investigate the efficacy and safety of osimertinib plus bevacizumab versus osimertinib montherapy in treatment-naïve recurrent or metastatic NSCLC patients…
- Trial name
- NCT04988607
- Testing
- Osimertinib, Bevacizumab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Guangdong Association of Clinical Trials
Carcinoma, Non-Small-Cell Lung, Genes, erbB-1
Osimertinib for NSCLC With Uncommon EGFR Mutations
This is a multi-center, retrospective study of ucEGFRmut (exon 20 insertions excluded) metastatic NSCLC osimertinib-treated as first EGFR inhibitor.
- Trial name
- UNICORN (NCT05421936)
- Testing
- Osimertinib
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Sheba Medical Center
Lung Cancer
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent RT and maintenance osimertinib in chemotherapy ineligible or refusal adult patients with Stage III…
- Trial name
- NSCLC (NCT07295821)
- Testing
- Osimertinib
- Where
- 20 sites in China
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Efficacy
AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC
The investigators want to evaluated the Efficay and Satety of PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC who Failed from First-Line Standard Treatment.
- Trial name
- Apple (NCT06196814)
- Testing
- PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy
- Volunteers
- 150 people
- Sponsor
- Hunan Province Tumor Hospital